Differential Susceptibility of Human Pleural and Peritoneal Mesothelial Cells to Asbestos Exposure

Journal of Cellular Biochemistry

Volumn 116, Issue 8, 2015, Pages 1540-1552

  Dragon, Julie ^a   Thompson, Joyce ^b   Macpherson, Maximilian ^b   Shukla, Arti ^b  

^a UNIVERSITY OF VERMONT   (United States)

^b UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

ASBESTOS; INFLAMMATION; MASSIVELY PARALLEL SEQUENCING; MESOTHELIAL CELLS; MESOTHELIOMA; RNA SEQ

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 3; CROCIDOLITE; CXCL1 CHEMOKINE; CXCL2 CHEMOKINE; CXCL3 CHEMOKINE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; DNA BINDING PROTEIN; GOS2 PROTEIN; GRANULOCYTE COLONY STIMULATING FACTOR; GREMLIN 1; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; NUCLEAR RECEPTOR NUR77; PROTEIN; PROTEIN C JUN; RNA; TRANSCRIPTION FACTOR AP 1; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CELL ACTIVITY; CELL COUNT; CELL GROWTH; CELL KILLING; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; FEMALE; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; INFLAMMATION; INTRACELLULAR SIGNALING; LUNG ALVEOLUS CELL; MALE; MESOTHELIUM CELL; MICROENVIRONMENT; MIDDLE AGED; OCCUPATIONAL EXPOSURE; ONCOGENE C FOS; PERITONEUM CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA SEQUENCE; SIGNAL TRANSDUCTION; UPREGULATION; CELL LINE; CELL SURVIVAL; CHEMICALLY INDUCED; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION; GENETICS; HIGH THROUGHPUT SEQUENCING; LUNG TUMOR; MESOTHELIOMA; PATHOLOGY; PERITONEUM TUMOR; PLEURA TUMOR; SEQUENCE ANALYSIS;

ADULT; AGED; ASBESTOS, CROCIDOLITE; CELL LINE; CELL SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC PREDISPOSITION TO DISEASE; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; INFLAMMATION; LUNG NEOPLASMS; MALE; MESOTHELIOMA; MIDDLE AGED; PERITONEAL NEOPLASMS; PLEURAL NEOPLASMS; SEQUENCE ANALYSIS, RNA;

EID: 84934930234     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.25095     Document Type: Article

References (45)

1. Adachi Y, Aoki C, et al., 2006. Interleukin-6 induces both cell growth and VEGF production in malignant mesotheliomas. Int J Cancer 119 (6): 1303-1311.
2. Adachi Y, Yoshio-Hoshino N, et al., 2010. VEGF targeting in mesotheliomas using an interleukin-6 signal inhibitor based on adenovirus gene delivery. Anticancer Res 30 (6): 1947-1952.
3. Amati M, Tomasetti M, et al., 2008. As sessment of biomarkers in asbestos-exposed workers as indicators of cancer risk. Mutat Res 655 (1-2): 52-58.
4. Anderson MJ, 2001. A new method for non-parametric multivariate analysis of variance. Austral Ecology 26: 32-46.
5. Benjamini Y, Hochberg Y,. 2009. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc. Series B (Methodological 57 (1): 289-300.
6. Bolger AM, Lohse M, et al., 2014. Trimmomatic: A flexible trimmer for Illumina sequence data. Bioinformatics 30 (15): 2114-2120.
7. Boylan AM, Ruegg C, et al., 1992. Evidence of a role for mesothelial cell-derived interleukin 8 in the pathogenesis of asbestos-induced pleurisy in rabbits. J Clin Invest 89 (4): 1257-1267.
8. Brunetti G, Delmastro M, et al., 2003. Immunocytological and mineralogical study of bronchoalveolar lavage in a group of subjects exposed to asbestos. G Ital Med Lav Ergon 25 (2): 152-160.
9. Choe N, Tanaka S, et al., 1998. Asbestos fibers and interleukin-1 upregulate the formation of reactive nitrogen species in rat pleural mesothelial cells. Am J Respir Cell Mol Biol 19 (2): 226-236.
10. Choe N, Zhang J, et al., 1999. Asbestos exposure upregulates the adhesion of pleural leukocytes to pleural mesothelial cells via VCAM-1. Am J Physiol 2 (Pt 1): L292-L300.
11. Corradi M, Goldoni M, et al., 2013. YKL-40 and mesothelin in the blood of patients with malignant mesothelioma, lung cancer and asbestosis. Anticancer Res 33 (12): 5517-5524.
12. Davidson B, Vintman L, et al., 2004. Heparanase and basic fibroblast growth factor are co-expressed in malignant mesothelioma. Clin Exp Metastasis 21 (5): 469-476.
13. Duncan KE, Cook PM, et al., 2014. In vitro determinants of asbestos fiber toxicity: Effect on the relative toxicity of Libby amphibole in primary human airway epithelial cells. Part Fibre Toxicol 11: 2.
14. Eikawa S, Ohue Y, et al., 2010. Enrichment of Foxp3+ CD4 regulatory T cells in migrated T cells to IL-6- and IL-8-expressing tumors through predominant induction of CXCR1 by IL-6. J Immunol 185 (11): 6734-6740.
15. Ferro A, Zebedeo CN, et al., 2014. Amphibole, but not chrysotile, asbestos induces anti-nuclear autoantibodies and IL-17 in C57BL/6 mice. J Immunotoxicol 11 (3): 283-290.
16. Griffith DE, Miller EJ, et al., 1994. Interleukin-1-mediated release of interleukin-8 by asbestos-stimulated human pleural mesothelial cells. Am J Respir Cell Mol Biol 10 (3): 245-252.
17. Hill GD, Mangum JB, et al., 2003. Soluble ICAM-1, MCP-1, and MIP-2 protein secretion by rat pleural mesothelial cells following exposure to amosite asbestos. Exp Lung Res 29 (5): 277-290.
18. Hillegass JM, Miller JM, et al., 2013. Asbestos and erionite prime and activate the NLRP3 inflammasome that stimulates autocrine cytokine release in human mesothelial cells. Part Fibre Toxicol 10: 39.
19. Hillegass JM, Shukla A, et al., 2010. Inflammation precedes the development of human malignant mesotheliomas in a SCID mouse xenograft model. Ann N Y Acad Sci 1203: 7-14.
20. Kanamori-Katayama M, Kaiho A, et al., 2011. LRRN4 and UPK3B are markers of primary mesothelial cells. PLoS One 6 (10) e5391.
21. Kindler HL, 2013. Peritoneal mesothelioma: The site of origin matters. Am Soc Clin Oncol Educ Book 33: 182-188.
22. Maeda M, Miura Y, et al., 2008. Immunological changes in mesothelioma patients and their experimental detection. Clin Med Circ Respirat Pulm Med 2: 11-17.
23. Mandl-Weber S, Haslinger B, et al., 2001. Heat-killed microorganisms induce PAI-1 expression in human peritoneal mesothelial cells: Role of interleukin-1alpha. Am J Kidney Dis 37 (4): 815-819.
24. Mills KH, Dungan LS, et al., 2013. The role of inflammasome-derived IL-1 in driving IL-17 responses. J Leukoc Biol 93 (4): 489-497.
25. Miserocchi G, 1997. Physiology and pathophysiology of pleural fluid turnover. Eur Respir J 10 (1): 219-225.
26. Miura Y, Nishimura Y, et al., 2006. Involvement of IL-10 and Bcl-2 in resistance against an asbestos-induced apoptosis of T cells. Apoptosis 11 (10): 1825-1835.
27. Mossman BT, Shukla A, et al., 2013. New insights into understanding the mechanisms, pathogenesis, and management of malignant mesotheliomas. Am J Pathol 182 (4): 1065-1077.
28. Mutsaers SE, 2004. The mesothelial cell. Int J Biochem Cell Biol 36 (1): 9-16.
29. Rodriguez D, Cheung MC, et al., 2009. Malignant abdominal mesothelioma: Defining the role of surgery. J Surg Oncol 99 (1): 51-57.
30. Shannahan JH, Ghio AJ, et al., 2012. Transcriptional activation of inflammasome components by Libby amphibole and the role of iron. Inhal Toxicol 24 (1): 60-69.
31. Shukla A, Barrett TF, et al., 2006. Transcriptional up-regulation of MMP12 and MMP13 by asbestos occurs via a PKCdelta-dependent pathway in murine lung. FASEB J 20 (7): 997-999.
32. Shukla A, MacPherson MB, et al., 2009. Alterations in gene expression in human mesothelial cells correlate with mineral pathogenicity. Am J Respir Cell Mol Biol 41 (1): 114-123.
33. Shukla A, Miller JM, et al., 2013. Extracellular signal-regulated kinase 5: A potential therapeutic target for malignant mesotheliomas. Clin Cancer Res 19 (8): 2071-2083.
34. Soderblom T, Pettersson T, et al., 1999. High pleural fluid hyaluronan concentrations in rheumatoid arthritis. Eur Respir J 13 (3): 519-522.
35. Tanaka T, Kanai H, et al., 2000. Induction of VEGF gene transcription by IL-1 beta is mediated through stress-activated MAP kinases and Sp1 sites in cardiac myocytes. J Mol Cell Cardiol 32 (11): 1955-1967.
36. Thompson JK, Westbom CM, et al., 2014. Malignant mesothelioma: Development to therapy. J Cell Biochem 115 (1): 1-7.
37. Trapnell C, Roberts A, et al., 2012. Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks. Nature Protocols 7 (3): 562-578.
38. Vlaeminck-Guillem V, Bienvenu J, et al., 2013. Intraperitoneal cytokine level in patients with peritoneal surface malignancies. A study of the RENAPE (French Network for Rare Peritoneal Malignancies). Ann Surg Oncol 20 (8): 2655-2662.
39. Wang Y, Faux SP, et al., 2004. Interleukin-1beta and tumour necrosis factor-alpha promote the transformation of human immortalised mesothelial cells by erionite. Int J Oncol 25 (1): 173-178.
40. Weber A, Wasiliew P, et al., 2010. Interleukin-1 (IL-1) pathway. Sci Signal. 3 (105): cm1.
41. Witowski J, Ksiazek K, et al., 2007. Role of mesothelial cell-derived granulocyte colony-stimulating factor in interleukin-17-induced neutrophil accumulation in the peritoneum. Kidney Int 71 (6): 514-525.
42. Wu D, Wu P, et al., 2013. Interleukin-17: A promoter in colorectal cancer progression. Clin Dev Immunol 2013: 436307.
43. Yoshimoto A, Kasahara K, et al., 2005. Granulocyte colony-stimulating factor-producing malignant pleural mesothelioma with the expression of other cytokines. Int J Clin Oncol 10 (1): 58-62.
44. Zarogoulidis P, Katsikogianni F, et al., 2014. Interleukin-8 and interleukin-17 for cancer. Cancer Invest 32 (5): 197-205.
45. Zebedeo CN, Davis C, et al., 2014. Erionite induces production of autoantibodies and IL-17 in C57BL/6 mice. Toxicol Appl Pharmacol 275 (3): 257-226.